Articles tagged with Tumor Cells
Researchers at the Niels Bohr Institute have developed a new cancer treatment that uses nanoparticles to transport cytotoxin directly to cancer cells via the bloodstream. The treatment has been shown to be effective in targeting and destroying cancer cells while leaving healthy cells unaffected.
Researchers developed a new screening protocol to detect human polyomaviruses in tumor samples, but found no association with various types of cancer. The technique will aid in studying diseases linked to polyomaviruses, such as Merkel cell carcinoma caused by Merkel cell polyomavirus.
Researchers have developed a new nanoparticle that kills tumor cells in the eye by mimicking an enzyme used by immune cells, extending survival of mice with advanced breast cancer. The treatment offers advantages such as producing toxins per hour and being activated by light.
A recent study published in Developmental Cell reveals that 68% of solid tumors are aneuploid, meaning they have an abnormal number of chromosomes. Aneuploidy contributes to genomic instability and cancer progression by triggering cell death and proliferation signals.
Researchers found that cancer cells kill off surrounding cells to make room to grow, but drugs that prevent cell death might be effective at fighting cancer. Manipulating genetic variants in surrounding cells can contain tumors and prevent their spread.
A recent study found that the presence of Epidermal Growth Factor (EGF) promotes the motility of elongated mesenchymal tumour cells in breast cancer cells, which migrate along collagen fibres. This increased persistence and moderate speed suggests that EGF contributes to modulating the mobility of tumour cells.
University of Iowa researchers track cancerous human breast tissue cells' motion and accretion into tumors, discovering that only five percent of cancerous cells are needed to form a tumor. The team finds that cancer cells actively recruit healthy cells by extending cables to grab their neighbors, forming a larger mass.
A new study published in Developmental Cell suggests that the KIF1Bβ gene plays a key role in determining whether neural crest cells live or die. The research team found that loss of KIF1B-β is associated with poor prognosis and reduced survival in neuroblastoma patients.
Researchers identified SGEF as a target for new brain cancer therapies in a study published by Molecular Cancer Research. The protein promotes the survival of glioblastoma tumor cells and helps the cancer invade brain tissue.
Scientists at University of California, San Diego discover protein Wnt5a stimulates CLL cell growth via ROR1 and ROR2 proteins. Experimental monoclonal antibody cirmtuzumab inhibits growth and spread of cancer cells.
Researchers discovered that aggressive tumors hijack an export pathway in cells to lay the groundwork for cancer progression and resistance to chemotherapy. Blocking this pathway may help restore tumor vulnerability to chemotherapy.
Researchers at Technical University of Munich create a highly active molecule that selectively targets the alphaVbeta6 integrin, a common marker in many types of cancer. This breakthrough could lead to patient-specific diagnoses and targeted therapies with minimal side effects.
Researchers used a novel approach to measure the forces exerted by tumor cells on their surrounding connective tissue. By analyzing tissue deformations, they calculated cell forces with high accuracy, revealing key insights into tumour cell migration and behaviour.
Researchers create spatiotemporal genomic analysis (SAGA) technique to study differences in cellular behavior, including cell migration and response to chemotherapy. This approach may lead to new treatments that hamper metastasis.
Research by Allison Cleary reveals that breast cancer cells work together to promote tumor growth, contradicting the long-held assumption of competitive interactions within tumors. Her findings have implications for developing novel treatments that target cooperative interactions in human breast cancers.
City of Hope researchers presented phase 1 clinical trial results for novel leukemia and lymphoma treatments, including targeted radiation and antibody therapy. The studies showed promising safety and efficacy outcomes, paving the way for future trials and potential improved patient outcomes.
A new study offers insights into how ovarian cancer grows, revealing a patterned hierarchy of cancer stem cells. The research identifies a key protein, BMP2, that regulates the growth of these stem-like cells. Targeting this protein could lead to more effective therapies for ovarian cancer.
Researchers have successfully combined an antibody-drug conjugate with immunotherapy to treat breast cancer. The therapy has shown promising results in attacking tumor cells and improving the body's immune response.
Researchers describe a new treatment option for glioblastoma multiforme, targeting malignant cells while leaving healthy cells alive with high-frequency pulsed electric fields. The therapy has shown promise in killing tumor cells by disrupting cell membranes and causing nuclear collapse.
A team of U of T engineers has developed a way to grow cancer cells in the form of a rolled-up sheet that mimics the 3D environment of a tumour, offering a way to speed up drug development and ask new questions about cell behavior. The single-layer design makes it easier for other lab researchers to adopt the process.
A new study by Siyuan Zhang and colleagues reveals that the microenvironment of tumor cells has a significant impact on cancer metastasis. The study suggests that the 'seed and soil' model, where tumors adapt to new tissues, can be used to prevent metastasis.
Researchers from NTU Singapore have successfully used dead bacteria to destroy colon tumour cells effectively. The study published in Scientific Reports shows that the secretions of dead Clostridium sporogenes bacteria can reduce the growth of colorectal cancer cells by up to 83%.
Researchers discovered brain cancer cells form a complex network to resist treatment and invade healthy brain tissue. The tumor cells use this network to communicate and repair damage, making it resistant to radiation therapy.
PharmaMar's novel Antibody-Drug Conjugate (ADC) MI130004 demonstrates potent anticancer activity against HER2-expressing breast, gastric, and ovarian cancers. The ADC impairs tubulin polymerization, causing mitotic failures and halting cell division in tumor cells.
A TSRI team has been awarded a $1.8 million grant to investigate the molecular mechanisms behind cancer metastasis. The research could lead to new approaches to help patients by targeting specific molecules involved in tumor cell survival and metastasis.
A new study from TSRI found that high levels of epidermal growth factor receptor (EGFR) encourage blood vessel growth in early tumor development, facilitating cancer cell dissemination and metastasis. The findings highlight the urgent need for new methods to diagnose cancers early and new treatments to fight growing metastases.
Researchers found that patrolling monocytes play a key role in blocking lung metastasis by recognizing and scavenging tumor cells. This discovery could lead to new treatments for lung cancer by augmenting existing immunotherapy approaches.
Researchers found that tumor suppressor protein PTEN is lost in brain cancer cells but restored once they migrate to other organs. This reversible loss enables brain metastases growth and protects against cell death.
A long-known tumor suppressor, pRb, works by restricting the activity of KDM5A, a molecule that regulates fuel burning in mitochondria. Cancer cells rely on fermenting sugars for energy, making them more vulnerable to metabolic therapies.
A team of researchers is using the Cray XK7 Titan supercomputer to simulate hundreds of millions of red blood cells in an attempt to develop better drug delivery methods and predictors for diseases like sickle cell anemia. The simulations are focused on understanding how these diseases interact with human blood vessels, particularly in...
Researchers have found a way to mobilize immune cells to attack and destroy malignant tumors by using a cell surface receptor called GITR. This protein can switch immature T-cells from becoming regulatory T-cells to tumor killers called Th9 cells, which produce the cancer-fighting protein interleukin 9.
Researchers discovered that cell programs controlling normal mammary gland stem cells differ from those regulating cancer stem cells, which arise in a distinct layer of tissue. This finding could lead to new cancer treatments by targeting the specific differences between normal and cancer cells.
Cancer cells can be made vulnerable to autophagy shutdown by combining an FLT3 inhibitor with an autophagy blocker. This combination prevents cancer cells from metabolizing glucose and mobilizing stored nutrients, leading to cell death. The study provides evidence that this approach could be a new way to treat various types of cancer.
Researchers found a core group of genes related to both viral defense and susceptibility to demethylating drug 5-azacytidine. The study suggests that triggering this pathway may improve the effectiveness of immunotherapy drugs in patients with certain types of cancer.
A Harvard University collaboration has developed a 3D model of solid tumors that reflects both their three-dimensional shape and genetic evolution. The model explains why cancer cells share an unusually high number of genetic mutations and how drug resistance evolves, shedding light on tumor growth and evolution.
Computer models of developing cancers show that small cell movements can quickly alter tumor composition. The models suggest treatments targeting these movements could slow disease progress by preventing certain cells from flourishing.
A new minimally invasive vaccine combines cancer cells with immune-enhancing factors, evoking an immune response in a simpler and more economical way. The approach has shown promising results in experimental animal models, shrinking tumors and protecting animals from tumor growth.
Researchers at Mayo Clinic have discovered a way to potentially reprogram cancer cells back to normalcy by restoring the expression of specific microRNAs. This finding represents an unexpected new biology that provides the code for turning off cancer, offering a potential strategy for cancer therapy.
A new study by the University of Pennsylvania School of Medicine has found that tumor cells associated with pancreatic cancer often behave like communities, working together to increase tumor spread and growth. The research suggests that interactions between subpopulations of tumor cell types contribute to metastatic progression.
A Brazilian antibody developed by Recepta Biopharma with FAPESP support will be used to create a new cancer drug. The technology has been licensed to US-based company Mersana Therapeutics, which will use it to develop an immunoconjugate against target tumor cells.
A new method called Time-lapse Imaging Microscopy in Nanowell Grids (TIMING) allows researchers to study immune cells and cancer cells in isolation, enabling the identification of high-performing outliers. This technology has the potential to expand cancer immunotherapy treatment options for more patients.
Researchers developed a biosensor to measure Mitochondrial Pyruvate Carrier (MPC) activity in malignant cells, finding low MPC activity compared to healthy cells. Treating cancer cells with a new compound restored normal MPC activity, suggesting the carrier's dysfunction is responsible for its inactivity.
Researchers have discovered that protein Hsp90 triggers cancer cell metabolism, providing a potential therapeutic target. The modified protein is toxic to cells in neurodegenerative disorders but acts as a pro-survival agent in tumor cells.
Researchers discovered that CA125-negative tumor cells have an enhanced ability to repair their DNA and resist programmed cell death, making them dangerous. Combining chemotherapy with birinapant significantly improved disease-free survival in laboratory models of human ovarian cancer.
Researchers at Lawson Health Research Institute have identified LKB1 as a key player in promoting and surviving ovarian cancer cells. This discovery contradicts previous studies, which suggested that LKB1 acts as a tumour suppressor in ovarian cancer.
Natural killer cells are impaired in the tumor microenvironment, but can be restored in normal conditions. Researchers identified two key factors blocking NK cell function: inflammatory cytokine IL-10 and down-regulated NKG2D ligands.
Researchers at University of Pennsylvania implicated defects in mitochondria as a key factor in cancerous cell transition. Disrupting mitochondrial components led normal cells to adopt cancerous characteristics, including increased glucose consumption and invasive behavior.
A recent study discovered that Daple protein is a tumor suppressor in the early stages of colorectal cancer, but may actually facilitate disease spread at later stages. Researchers found that higher levels of Daple were associated with better patient survival rates and lower tumor growth.
Ghajar is investigating two approaches: keeping dormant cells asleep or destroying them altogether to prevent breast cancer metastasis. He aims to identify factors that keep cells asleep and profile molecules that mediate chemo resistance, potentially providing a lasting cure for cancer patients.
Scientists at the Salk Institute discovered that telomeres play a more central role in a self-destruct program in cells that prevents tumors than previously thought. This process, called crisis, can be exploited to improve cancer therapies by targeting telomeres and making cells more susceptible to chemotherapy.
A new study suggests that cell fusion can initiate cancerous processes and tumor formation through 'genomic catastrophe', leading to chromosomal instability and DNA damage. Fused cells from rat intestinal epithelial cells formed tumors in immunodeficient mice, providing evidence for a molecular mechanism driving neoplastic transformation.
The combination of MEDI4736 and tremelimumab has been shown to have manageable toxicity and clinical activity in advanced NSCLC patients, including those with PD-L1 negative tumors. Eight out of 31 evaluable patients achieved a partial response.
Differences in tumor cell metabolism lead to more aggressive behavior in the center of a tumor. Mathematical modeling shows that cells with high glucose metabolism and acid production become invasive and cause tumor recurrence.
Researchers developed a microfluidic device called the Cluster-Chip to capture clusters of two or more cells, which are significantly more likely to cause metastases. The device proved 40-50% better at finding clusters with targeted markers and 1000% better at capturing cells without them.
Dying daughter cells release protein Pvf1, binding to nearby mother stem cells' receptors, preventing apoptosis. This allows stem cells to survive until they can regenerate damaged tissue. The discovery may lead to new cancer treatments by targeting protective signals in tumor-initiating cells.
Scientists at The Wistar Institute have identified a way that cells can reprogram their metabolism to overcome senescence, a tumor-suppressing mechanism. This reprogramming allows for the proliferation of cells that should have become senescent and has the potential to lead to tumor formation.
Researchers at the University of Notre Dame investigate the clinical potential of microvesicles, shedding light on their role in promoting tumor invasion and metastasis. The study identifies key proteins that guide the formation of these vesicles and suggests a potential link to biomarker development.
Researchers have identified a novel approach to treating pancreatic cancer by introducing the protein E47, which can reprogram cancer cells back to their original state. This breakthrough offers new therapeutic possibilities and may lead to improved patient outcomes.
Researchers discovered that Myc's primary function is to repress well-being genes, making cancer cells vulnerable to cell death. This finding suggests a new approach for cancer therapies, targeting the downregulation of well-being genes to enhance the killer activity of Myc in tumor cells.
Scientists at MIT created a new cancer therapy that activates both the innate and adaptive immune systems to attack tumors. The treatment combines an antibody drug with IL-2, which boosts immune responses, resulting in complete tumor disappearance in 80-90% of mice.